MedPath

An Investigator-initiated, Explorative Trial Evaluating the Effect of SAT-008 in Healthy Adults

Not Applicable
Completed
Conditions
Allergy and Immunology
Registration Number
NCT04916145
Lead Sponsor
Seoul National University Bundang Hospital
Brief Summary

The purpose of this exploratory study is to evaluate the efficacy, safety, and feasibility of a novel digital device called SAT-008 in healthy adults.

Detailed Description

This clinical study was designed as a single institution, open, controlled, and investigator-led clinical trial to evaluate the efficacy, safety, and feasibility of a novel digital device called SAT-008 in healthy adults.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
42
Inclusion Criteria
  • Healthy adults aged 19 to 50 years
  • Received influenza vaccination the previous year
  • Scheduled to receive the influenza vaccine
  • Voluntarily agrees with a consent form
Exclusion Criteria
  • Current infectious disease
  • History of autoimmune diseases
  • Current immunological compromised diseases.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Changes in functions of immunocytesBaseline, Week 1, Week 5, Week 13

To measure changes in functions of natural killer cells, T cells, and B cells at 1, 5, and 13 weeks compared to baseline.

Number of expected and unexpected adverse eventsWeek 13 (thirteen weeks following baseline)

To evaluate the safety of SAT-008

Rate of adherence to SAT-008Week 13 (thirteen weeks following baseline)

To assess a degree to which participants follow SAT-008

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Seoul National University Bundang Hospital

🇰🇷

Seongnam-si, Gyeonggi-do, Korea, Republic of

Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.